Please login to the form below
mirabegron
This page shows the latest mirabegron news and features for those working in and with pharma, biotech and healthcare.
Urovant slips on phase 3 incontinence drug data
Vibegron was licensed from Merck &Co/MSD in 2017 and is billed as an improved version of Astellas’ Myrbetriq/Betmiga (mirabegron), which was the first beta3-adrenergic agonist to reach the
Latest news
-
Germany’s IQWiG denies Astellas’ incontinence drug
IQWiG, which assesses the cost-effectiveness of treatments for reimbursement in Germany, published an evaluation of Astellas' Betmiga (mirabegron) that does not recommend its use in the treatment of overactive bladder
-
Astellas gets first OK for prostate drug Vesomni
The company has already added to its OAB franchise with the approval of Myrbetriq/Betanis (mirabegron) in Japan in 2011 and the US last year, and has said in the past
-
NICE recommends Astellas' Betmiga for overactive bladder
The National Institute for Health and Care Excellence (NICE) said in final draft guidance that Astellas' Betmiga (mirabegron) was an efficient use of NHS resources to treat people with overactive bladder ... Offering mirabegron as an option for treatment,
-
European approval for Astellas' first-in-class bladder drug Betmiga
Will compete with Pfizer's Detrol and Astellas' own Vesicare. The European Commission has approved Astellas' overactive bladder treatment Betmiga (mirabegron).
-
Range of approvals in Japan
Tokyo-based Astellas also received news of Japanese approvals, including Betanis (mirabegron) for use in the treatment of overactive bladder, and Recalbon (minodronic acid hydrate) for use in osteoporosis.
More from news
Approximately 3 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Astellas: Ten years young
In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new
-
Interview: Ken Jones, Astellas Pharma Europe
Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
